Zelira’s HOPE 1 SPV Secures Transformative US$33m Funding Commitments

Zelira Therapeutics ( (AU:ZLD) ) just unveiled an announcement.

Zelira Therapeutics has advanced funding plans for its HOPE® 1 special purpose vehicle, with definitive agreements in place for a US$32.98 million capital raising that values the SPV at about US$65.96 million and Zelira’s diluted stake at roughly US$26.19 million. Despite complications delaying the closing and necessitating an extension of the fundraising deadline, Zelira and partner ThirdGate Capital remain committed to completing the transaction, which will fund FDA clinical progress for HOPE® 1, including an IND submission, initiation of a Phase 1 trial, and an Orphan Drug Designation filing, while also covering licence fees for Zyraydi technology to reformulate HOPE® 1 into a more cost-efficient capsule.

The fundraising is positioned as a transformative step for Zelira’s HOPE® franchise, reinforcing investor confidence in the company’s science and its strategy to utilise the FDA’s 505(b)(2) pathway. Successful closure and deployment of the capital are expected to accelerate HOPE® 1’s regulatory journey, enhance the competitiveness of its dosage form, and potentially strengthen Zelira’s standing in the cannabinoid-based therapeutics market, with implications for patients, clinicians and shareholders as the autism-focused program advances.

More about Zelira Therapeutics

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is a global biotechnology company focused on the development and commercialisation of clinically validated cannabinoid-based medicines. The company targets conditions such as autism with its HOPE® portfolio, aiming to navigate accelerated U.S. FDA regulatory pathways and expand its presence in specialised therapeutic markets.

Average Trading Volume: 8,355

Technical Sentiment Signal: Buy

Current Market Cap: A$5.95M

See more insights into ZLD stock on TipRanks’ Stock Analysis page.